{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T15:30:38Z","timestamp":1795102238595,"version":"4.10.3"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["75N93019C00050"],"award-info":[{"award-number":["75N93019C00050"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-024-52940-z","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T15:02:09Z","timestamp":1728399729000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Improved influenza vaccine responses after expression of multiple viral glycoproteins from a single mRNA"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3404-0399","authenticated-orcid":false,"given":"Rebecca A.","family":"Leonard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlyn N.","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1254-0760","authenticated-orcid":false,"given":"Rachel L.","family":"Spreng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew N.","family":"Macintyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4083-5251","authenticated-orcid":false,"given":"Ying","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5672-6930","authenticated-orcid":false,"given":"Mohamad-Gabriel","family":"Alameh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew","family":"Weissman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5307-3428","authenticated-orcid":false,"given":"Nicholas S.","family":"Heaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,8]]},"reference":[{"key":"52940_CR1","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1001\/jama.292.11.1333","volume":"292","author":"WW Thompson","year":"2004","unstructured":"Thompson, W. W. et al. Influenza-associated hospitalizations in the United States. JAMA 292, 1333\u20131340 (2004).","journal-title":"JAMA"},{"key":"52940_CR2","unstructured":"Prevention, C.f.D.C.a. Preliminary Estimated Influenza Illnesses, Medical Visits, Hospitalizations, and Deaths in the United States\u20142022\u20132023 Influenza Season. 2024 (2023)."},{"key":"52940_CR3","doi-asserted-by":"publisher","first-page":"3960","DOI":"10.1016\/j.vaccine.2018.05.057","volume":"36","author":"W Putri","year":"2018","unstructured":"Putri, W., Muscatello, D. J., Stockwell, M. S. & Newall, A. T. Economic burden of seasonal influenza in the United States. Vaccine 36, 3960\u20133966 (2018).","journal-title":"Vaccine"},{"key":"52940_CR4","first-page":"767","volume":"70","author":"D Hobson","year":"1972","unstructured":"Hobson, D., Curry, R. L., Beare, A. S. & Ward-Gardner, A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J. Hyg. (Lond.) 70, 767\u2013777 (1972).","journal-title":"J. Hyg. (Lond.)"},{"key":"52940_CR5","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cell.2018.03.030","volume":"173","author":"YQ Chen","year":"2018","unstructured":"Chen, Y. Q. et al. Influenza infection in humans induces broadly cross-reactive and protective neuraminidase-reactive antibodies. Cell 173, 417\u2013429.e410 (2018).","journal-title":"Cell"},{"key":"52940_CR6","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/s41573-019-0056-x","volume":"19","author":"CJ Wei","year":"2020","unstructured":"Wei, C. J. et al. Next-generation influenza vaccines: opportunities and challenges. Nat. Rev. Drug Discov. 19, 239\u2013252 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"52940_CR7","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/nsb0298-119","volume":"5","author":"D Fleury","year":"1998","unstructured":"Fleury, D., Wharton, S. A., Skehel, J. J., Knossow, M. & Bizebard, T. Antigen distortion allows influenza virus to escape neutralization. Nat. Struct. Biol. 5, 119\u2013123 (1998).","journal-title":"Nat. Struct. Biol."},{"key":"52940_CR8","doi-asserted-by":"publisher","first-page":"eabg4535","DOI":"10.1126\/scitranslmed.abg4535","volume":"13","author":"JJ Guthmiller","year":"2021","unstructured":"Guthmiller, J. J. et al. First exposure to the pandemic H1N1 virus induced broadly neutralizing antibodies targeting hemagglutinin head epitopes. Sci. Transl. Med. 13, eabg4535 (2021).","journal-title":"Sci. Transl. Med."},{"key":"52940_CR9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3390\/vaccines6030035","volume":"6","author":"T Yamazaki","year":"2018","unstructured":"Yamazaki, T., Chiba, J. & Akashi-Takamura, S. Neutralizing anti-hemagglutinin monoclonal antibodies induced by gene-based transfer have prophylactic and therapeutic effects on influenza virus infection. Vaccines (Basel) 6, 35 (2018).","journal-title":"Vaccines (Basel)"},{"key":"52940_CR10","doi-asserted-by":"publisher","first-page":"187ra170","DOI":"10.1126\/scitranslmed.3005996","volume":"5","author":"RA Medina","year":"2013","unstructured":"Medina, R. A. et al. Glycosylations in the globular head of the hemagglutinin protein modulate the virulence and antigenic properties of the H1N1 influenza viruses. Sci. Transl. Med. 5, 187ra170 (2013).","journal-title":"Sci. Transl. Med."},{"key":"52940_CR11","doi-asserted-by":"publisher","first-page":"20248","DOI":"10.1073\/pnas.1320524110","volume":"110","author":"NS Heaton","year":"2013","unstructured":"Heaton, N. S., Sachs, D., Chen, C. J., Hai, R. & Palese, P. Genome-wide mutagenesis of influenza virus reveals unique plasticity of the hemagglutinin and NS1 proteins. Proc. Natl. Acad. Sci. USA 110, 20248\u201320253 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"52940_CR12","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/s41577-019-0143-6","volume":"19","author":"F Krammer","year":"2019","unstructured":"Krammer, F. The human antibody response to influenza A virus infection and vaccination. Nat. Rev. Immunol. 19, 383\u2013397 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"52940_CR13","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1146\/annurev-virology-010320-044746","volume":"7","author":"S Gouma","year":"2020","unstructured":"Gouma, S., Anderson, E. M. & Hensley, S. E. Challenges of making effective influenza vaccines. Annu. Rev. Virol. 7, 495\u2013512 (2020).","journal-title":"Annu. Rev. Virol."},{"key":"52940_CR14","doi-asserted-by":"publisher","first-page":"e02332","DOI":"10.1128\/mBio.02332-17","volume":"9","author":"F Krammer","year":"2018","unstructured":"Krammer, F. et al. NAction! How can neuraminidase-based immunity contribute to better influenza virus vaccines? mBio 9, e02332\u201317 (2018).","journal-title":"mBio"},{"key":"52940_CR15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.it.2023.11.001","volume":"45","author":"NC Wu","year":"2024","unstructured":"Wu, N. C. & Ellebedy, A. H. Targeting neuraminidase: the next frontier for broadly protective influenza vaccines. Trends Immunol. 45, 11\u201319 (2024).","journal-title":"Trends Immunol."},{"key":"52940_CR16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12929-020-0626-6","volume":"27","author":"JR Chen","year":"2020","unstructured":"Chen, J. R., Liu, Y. M., Tseng, Y. C. & Ma, C. Better influenza vaccines: an industry perspective. J. Biomed. Sci. 27, 33 (2020).","journal-title":"J. Biomed. Sci."},{"key":"52940_CR17","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01723-22","volume":"97","author":"S Gouma","year":"2023","unstructured":"Gouma, S. et al. Nucleoside-modified mRNA-based influenza vaccines circumvent problems associated with H3N2 vaccine strain egg adaptation. J. Virol. 97, e0172322 (2023).","journal-title":"J. Virol."},{"key":"52940_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-11-153","volume":"11","author":"AC Tricco","year":"2013","unstructured":"Tricco, A. C. et al. Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis. BMC Med 11, 153 (2013).","journal-title":"BMC Med"},{"key":"52940_CR19","doi-asserted-by":"publisher","first-page":"12578","DOI":"10.1073\/pnas.1712377114","volume":"114","author":"SJ Zost","year":"2017","unstructured":"Zost, S. J. et al. Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. Proc. Natl. Acad. Sci. USA 114, 12578\u201312583 (2017).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"52940_CR20","doi-asserted-by":"publisher","first-page":"e2022058143","DOI":"10.1542\/peds.2022-058143","volume":"150","author":"JL Nayak","year":"2022","unstructured":"Nayak, J. L. & Caserta, M. T. Cell-culture-based influenza vaccines: don\u2019t put all of your influenza vaccines in the egg basket. Pediatrics 150, e2022058143 (2022).","journal-title":"Pediatrics"},{"key":"52940_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.celrep.2015.06.005","volume":"12","author":"BS Chambers","year":"2015","unstructured":"Chambers, B. S., Parkhouse, K., Ross, T. M., Alby, K. & Hensley, S. E. Identification of hemagglutinin residues responsible for H3N2 antigenic drift during the 2014-2015 influenza season. Cell Rep. 12, 1\u20136 (2015).","journal-title":"Cell Rep."},{"key":"52940_CR22","unstructured":"Prevention, C.f.D.C.a. CDC Seasonal Flu Vaccine Effectiveness Studies, https:\/\/www.cdc.gov\/flu-vaccines-work\/php\/effectiveness-studies\/index.html 2024 (2024)."},{"key":"52940_CR23","doi-asserted-by":"publisher","first-page":"abm0829","DOI":"10.1126\/science.abm0829","volume":"374","author":"RR Goel","year":"2021","unstructured":"Goel, R. R. et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science 374, abm0829 (2021).","journal-title":"Science"},{"key":"52940_CR24","unstructured":"Goel, R. R. et al. mRNA vaccination induces durable immune memory to SARS-CoV-2 with continued evolution to variants of concern. bioRxiv (2021)."},{"key":"52940_CR25","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/j.immuni.2021.08.001","volume":"54","author":"MM Painter","year":"2021","unstructured":"Painter, M. M. et al. Rapid induction of antigen-specific CD4(+) T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination. Immunity 54, 2133\u20132142 e2133 (2021).","journal-title":"Immunity"},{"key":"52940_CR26","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","volume":"20","author":"N Chaudhary","year":"2021","unstructured":"Chaudhary, N., Weissman, D. & Whitehead, K. A. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat. Rev. Drug Discov. 20, 817\u2013838 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"52940_CR27","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41392-023-01579-1","volume":"8","author":"G Zhang","year":"2023","unstructured":"Zhang, G., Tang, T., Chen, Y., Huang, X. & Liang, T. mRNA vaccines in disease prevention and treatment. Signal Transduct. Target Ther. 8, 365 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"52940_CR28","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403\u2013416 (2021).","journal-title":"N. Engl. J. Med."},{"key":"52940_CR29","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med"},{"key":"52940_CR30","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1056\/NEJMoa2307079","volume":"389","author":"E Wilson","year":"2023","unstructured":"Wilson, E. et al. Efficacy and safety of an mRNA-Based RSV PreF vaccine in older adults. N. Engl. J. Med 389, 2233\u20132244 (2023).","journal-title":"N. Engl. J. Med"},{"key":"52940_CR31","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1056\/NEJMoa2203315","volume":"386","author":"CB Creech","year":"2022","unstructured":"Creech, C. B. et al. Evaluation of mRNA-1273 Covid-19 vaccine in children 6 to 11 years of age. N. Engl. J. Med 386, 2011\u20132023 (2022).","journal-title":"N. Engl. J. Med"},{"key":"52940_CR32","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1136\/annrheumdis-2021-220647","volume":"80","author":"V Furer","year":"2021","unstructured":"Furer, V. et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann. Rheum. Dis. 80, 1330\u20131338 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"52940_CR33","first-page":"e45602","volume":"15","author":"YF Jamous","year":"2023","unstructured":"Jamous, Y. F. & Alhomoud, D. A. The safety and effectiveness of mRNA vaccines against SARS-CoV-2. Cureus 15, e45602 (2023).","journal-title":"Cureus"},{"key":"52940_CR34","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrd4278","volume":"13","author":"U Sahin","year":"2014","unstructured":"Sahin, U., Kariko, K. & Tureci, O. mRNA-based therapeutics\u2013developing a new class of drugs. Nat. Rev. Drug Discov. 13, 759\u2013780 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"key":"52940_CR35","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.coi.2018.03.025","volume":"53","author":"MC Eichelberger","year":"2018","unstructured":"Eichelberger, M. C., Morens, D. M. & Taubenberger, J. K. Neuraminidase as an influenza vaccine antigen: a low hanging fruit, ready for picking to improve vaccine effectiveness. Curr. Opin. Immunol. 53, 38\u201344 (2018).","journal-title":"Curr. Opin. Immunol."},{"key":"52940_CR36","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1093\/infdis\/jiv195","volume":"212","author":"AS Monto","year":"2015","unstructured":"Monto, A. S. et al. Antibody to influenza virus neuraminidase: an independent correlate of protection. J. Infect. Dis. 212, 1191\u20131199 (2015).","journal-title":"J. Infect. Dis."},{"key":"52940_CR37","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3390\/vaccines8030409","volume":"8","author":"LT Giurgea","year":"2020","unstructured":"Giurgea, L. T., Morens, D. M., Taubenberger, J. K. & Memoli, M. J. Influenza neuraminidase: a neglected protein and its potential for a better influenza vaccine. Vaccines (Basel) 8, 409 (2020).","journal-title":"Vaccines (Basel)"},{"key":"52940_CR38","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/j.immuni.2023.07.004","volume":"56","author":"L Hansen","year":"2023","unstructured":"Hansen, L. et al. Human anti-N1 monoclonal antibodies elicited by pandemic H1N1 virus infection broadly inhibit HxN1 viruses in vitro and in vivo. Immunity 56, 1927\u20131938.e1928 (2023).","journal-title":"Immunity"},{"key":"52940_CR39","doi-asserted-by":"publisher","first-page":"e02315","DOI":"10.1128\/mBio.02315-20","volume":"11","author":"H Jiang","year":"2020","unstructured":"Jiang, H. et al. Structure-based modification of an anti-neuraminidase human antibody restores protection efficacy against the drifted influenza virus. mBio 11, e02315\u2013e02320 (2020).","journal-title":"mBio"},{"key":"52940_CR40","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1073\/pnas.87.2.786","volume":"87","author":"ED Kilbourne","year":"1990","unstructured":"Kilbourne, E. D., Johansson, B. E. & Grajower, B. Independent and disparate evolution in nature of influenza A virus hemagglutinin and neuraminidase glycoproteins. Proc. Natl. Acad. Sci. USA 87, 786\u2013790 (1990).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"52940_CR41","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1126\/science.aay0678","volume":"366","author":"D Stadlbauer","year":"2019","unstructured":"Stadlbauer, D. et al. Broadly protective human antibodies that target the active site of influenza virus neuraminidase. Science 366, 499\u2013504 (2019).","journal-title":"Science"},{"key":"52940_CR42","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.02556-14","volume":"6","author":"TJ Wohlbold","year":"2015","unstructured":"Wohlbold, T. J. et al. Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice. mBio 6, e02556 (2015).","journal-title":"mBio"},{"key":"52940_CR43","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2206333119","volume":"119","author":"M McMahon","year":"2022","unstructured":"McMahon, M. et al. Assessment of a quadrivalent nucleoside-modified mRNA vaccine that protects against group 2 influenza viruses. Proc. Natl. Acad. Sci. USA 119, e2206333119 (2022).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"52940_CR44","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.ijbiomac.2022.12.066","volume":"226","author":"N Rcheulishvili","year":"2023","unstructured":"Rcheulishvili, N. et al. Designing multi-epitope mRNA construct as a universal influenza vaccine candidate for future epidemic\/pandemic preparedness. Int. J. Biol. Macromol. 226, 885\u2013899 (2023).","journal-title":"Int. J. Biol. Macromol."},{"key":"52940_CR45","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01646-22","volume":"97","author":"WF Rijnink","year":"2023","unstructured":"Rijnink, W. F. et al. Characterization of non-neutralizing human monoclonal antibodies that target the M1 and NP of influenza A viruses. J. Virol. 97, e0164622 (2023).","journal-title":"J. Virol."},{"key":"52940_CR46","unstructured":"Moderna, I. Moderna Announces Interim Phase 3 Safety and Immunogenicity Results for mRNA-1010, a Seasonal Influenza Vaccine Candidate. (2023)."},{"key":"52940_CR47","unstructured":"Moderna, I. Moderna Announces First Participants Dosed in Phase 1\/2 Study with mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccine Candidates. (2022)."},{"key":"52940_CR48","doi-asserted-by":"publisher","first-page":"300","DOI":"10.3390\/vaccines12030300","volume":"12","author":"M Li","year":"2024","unstructured":"Li, M. et al. Influenza a neuraminidase-based bivalent mRNA vaccine induces Th1-type immune response and provides protective effects in mice. Vaccines (Basel) 12, 300 (2024).","journal-title":"Vaccines (Basel)"},{"key":"52940_CR49","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/j.ymthe.2020.04.018","volume":"28","author":"AW Freyn","year":"2020","unstructured":"Freyn, A. W. et al. A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice. Mol. Ther. 28, 1569\u20131584 (2020).","journal-title":"Mol. Ther."},{"key":"52940_CR50","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1126\/science.abm0271","volume":"378","author":"CP Arevalo","year":"2022","unstructured":"Arevalo, C. P. et al. A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes. Science 378, 899\u2013904 (2022).","journal-title":"Science"},{"key":"52940_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32149-8","volume":"13","author":"N Pardi","year":"2022","unstructured":"Pardi, N. et al. Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses. Nat. Commun. 13, 4677 (2022).","journal-title":"Nat. Commun."},{"key":"52940_CR52","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/0168-1702(85)90060-7","volume":"2","author":"S Basak","year":"1985","unstructured":"Basak, S., Tomana, M. & Compans, R. W. Sialic acid is incorporated into influenza hemagglutinin glycoproteins in the absence of viral neuraminidase. Virus Res. 2, 61\u201368 (1985).","journal-title":"Virus Res."},{"key":"52940_CR53","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/0042-6822(74)90276-1","volume":"61","author":"P Palese","year":"1974","unstructured":"Palese, P., Tobita, K., Ueda, M. & Compans, R. W. Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. Virology 61, 397\u2013410 (1974).","journal-title":"Virology"},{"key":"52940_CR54","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3389\/fmicb.2019.00039","volume":"10","author":"JL McAuley","year":"2019","unstructured":"McAuley, J. L., Gilbertson, B. P., Trifkovic, S., Brown, L. E. & McKimm-Breschkin, J. L. Influenza virus neuraminidase structure and functions. Front Microbiol. 10, 39 (2019).","journal-title":"Front Microbiol."},{"key":"52940_CR55","doi-asserted-by":"publisher","first-page":"e8495","DOI":"10.1371\/journal.pone.0008495","volume":"4","author":"B Su","year":"2009","unstructured":"Su, B. et al. Enhancement of the influenza A hemagglutinin (HA)-mediated cell-cell fusion and virus entry by the viral neuraminidase (NA). PLoS One 4, e8495 (2009).","journal-title":"PLoS One"},{"key":"52940_CR56","doi-asserted-by":"publisher","first-page":"12075","DOI":"10.1128\/JVI.00046-10","volume":"84","author":"F Li","year":"2010","unstructured":"Li, F. et al. Generation of replication-competent recombinant influenza A viruses carrying a reporter gene harbored in the neuraminidase segment. J. Virol. 84, 12075\u201312081 (2010).","journal-title":"J. Virol."},{"key":"52940_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3369","volume":"4","author":"W Pan","year":"2013","unstructured":"Pan, W. et al. Visualizing influenza virus infection in living mice. Nat. Commun. 4, 2369 (2013).","journal-title":"Nat. Commun."},{"key":"52940_CR58","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1038\/sj.mt.6300142","volume":"15","author":"J Fang","year":"2007","unstructured":"Fang, J. et al. An antibody delivery system for regulated expression of therapeutic levels of monoclonal antibodies in vivo. Mol. Ther. 15, 1153\u20131159 (2007).","journal-title":"Mol. Ther."},{"key":"52940_CR59","doi-asserted-by":"publisher","first-page":"e00669","DOI":"10.1128\/mBio.00669-17","volume":"8","author":"AT Harding","year":"2017","unstructured":"Harding, A. T., Heaton, B. E., Dumm, R. E. & Heaton, N. S. Rationally designed influenza virus vaccines that are antigenically stable during growth in eggs. mBio 8, e00669\u201317 (2017).","journal-title":"mBio"},{"key":"52940_CR60","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1016\/j.immuni.2021.11.001","volume":"54","author":"MG Alameh","year":"2021","unstructured":"Alameh, M. G. et al. Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. Immunity 54, 2877\u20132892 e2877 (2021).","journal-title":"Immunity"},{"key":"52940_CR61","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1242\/dmm.007823","volume":"4","author":"JA Belser","year":"2011","unstructured":"Belser, J. A., Katz, J. M. & Tumpey, T. M. The ferret as a model organism to study influenza A virus infection. Dis. Model Mech. 4, 575\u2013579 (2011).","journal-title":"Dis. Model Mech."},{"key":"52940_CR62","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1172\/JCI84428","volume":"126","author":"DJ DiLillo","year":"2016","unstructured":"DiLillo, D. J., Palese, P., Wilson, P. C. & Ravetch, J. V. Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection. J. Clin. Invest 126, 605\u2013610 (2016).","journal-title":"J. Clin. Invest"},{"key":"52940_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05482-0","volume":"9","author":"N Pardi","year":"2018","unstructured":"Pardi, N. et al. Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies. Nat. Commun. 9, 3361 (2018).","journal-title":"Nat. Commun."},{"key":"52940_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100793","volume":"3","author":"JME Lim","year":"2022","unstructured":"Lim, J. M. E. et al. A comparative characterization of SARS-CoV-2-specific T cells induced by mRNA or inactive virus COVID-19 vaccines. Cell Rep. Med 3, 100793 (2022).","journal-title":"Cell Rep. Med"},{"key":"52940_CR65","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/j.ymthe.2021.05.011","volume":"29","author":"CJ Knudson","year":"2021","unstructured":"Knudson, C. J. et al. Lipid-nanoparticle-encapsulated mRNA vaccines induce protective memory CD8 T cells against a lethal viral infection. Mol. Ther. 29, 2769\u20132781 (2021).","journal-title":"Mol. Ther."},{"key":"52940_CR66","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1038\/s41590-022-01313-z","volume":"23","author":"N Brasu","year":"2022","unstructured":"Brasu, N. et al. Memory CD8(+) T cell diversity and B cell responses correlate with protection against SARS-CoV-2 following mRNA vaccination. Nat. Immunol. 23, 1445\u20131456 (2022).","journal-title":"Nat. Immunol."},{"key":"52940_CR67","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1128\/cdli.3.5.511-516.1996","volume":"3","author":"DC Powers","year":"1996","unstructured":"Powers, D. C., Kilbourne, E. D. & Johansson, B. E. Neuraminidase-specific antibody responses to inactivated influenza virus vaccine in young and elderly adults. Clin. Diagn. Lab Immunol. 3, 511\u2013516 (1996).","journal-title":"Clin. Diagn. Lab Immunol."},{"key":"52940_CR68","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.vaccine.2012.10.065","volume":"31","author":"RB Couch","year":"2012","unstructured":"Couch, R. B. et al. Randomized comparative study of the serum antihemagglutinin and antineuraminidase antibody responses to six licensed trivalent influenza vaccines. Vaccine 31, 190\u2013195 (2012).","journal-title":"Vaccine"},{"key":"52940_CR69","doi-asserted-by":"publisher","first-page":"20748","DOI":"10.1073\/pnas.1113801108","volume":"108","author":"MR Sandbulte","year":"2011","unstructured":"Sandbulte, M. R. et al. Discordant antigenic drift of neuraminidase and hemagglutinin in H1N1 and H3N2 influenza viruses. Proc. Natl. Acad. Sci. USA 108, 20748\u201320753 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"52940_CR70","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofu115","volume":"2","author":"MR Laguio-Vila","year":"2015","unstructured":"Laguio-Vila, M. R. et al. Comparison of serum hemagglutinin and neuraminidase inhibition antibodies after 2010-2011 trivalent inactivated influenza vaccination in healthcare personnel. Open Forum Infect. Dis. 2, ofu115 (2015).","journal-title":"Open Forum Infect. Dis."},{"key":"52940_CR71","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/978-1-4613-1663-3_2","volume":"228","author":"R Schauer","year":"1988","unstructured":"Schauer, R. Sialic acids as antigenic determinants of complex carbohydrates. Adv. Exp. Med Biol. 228, 47\u201372 (1988).","journal-title":"Adv. Exp. Med Biol."},{"key":"52940_CR72","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.omtn.2019.02.018","volume":"15","author":"M Baiersdorfer","year":"2019","unstructured":"Baiersdorfer, M. et al. A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA. Mol. Ther. Nucleic Acids 15, 26\u201335 (2019).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"52940_CR73","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1038\/mt.2013.124","volume":"21","author":"MA Maier","year":"2013","unstructured":"Maier, M. A. et al. Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. Mol. Ther. 21, 1570\u20131578 (2013).","journal-title":"Mol. Ther."},{"key":"52940_CR74","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/nm.3927","volume":"21","author":"HM Yassine","year":"2015","unstructured":"Yassine, H. M. et al. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat. Med 21, 1065\u20131070 (2015).","journal-title":"Nat. Med"},{"key":"52940_CR75","doi-asserted-by":"publisher","first-page":"e02810","DOI":"10.1128\/mBio.02810-18","volume":"10","author":"KS Corbett","year":"2019","unstructured":"Corbett, K. S. et al. Design of nanoparticulate group 2 influenza virus hemagglutinin stem antigens that activate unmutated ancestor B cell receptors of broadly neutralizing antibody lineages. mBio 10, e02810\u2013e02818 (2019).","journal-title":"mBio"},{"key":"52940_CR76","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.7150\/ijbs.59233","volume":"17","author":"JW Park","year":"2021","unstructured":"Park, J. W., Lagniton, P. N. P., Liu, Y. & Xu, R. H. mRNA vaccines for COVID-19: what, why and how. Int. J. Biol. Sci. 17, 1446\u20131460 (2021).","journal-title":"Int. J. Biol. Sci."},{"key":"52940_CR77","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41586-021-03275-y","volume":"592","author":"AB Vogel","year":"2021","unstructured":"Vogel, A. B. et al. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature 592, 283\u2013289 (2021).","journal-title":"Nature"},{"key":"52940_CR78","doi-asserted-by":"publisher","first-page":"14216","DOI":"10.1073\/pnas.1111497108","volume":"108","author":"JR Whittle","year":"2011","unstructured":"Whittle, J. R. et al. Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc. Natl. Acad. Sci. USA 108, 14216\u201314221 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-52940-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-52940-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-52940-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T18:06:54Z","timestamp":1728410814000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-52940-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,8]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["52940"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-52940-z","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,8]]},"assertion":[{"value":"24 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Duke University has filed for protection of intellectual property related to the vaccine approach described in this manuscript on behalf of N.S.H. Y.T. is an officer with Acuitas Therapeutics, a company dedicated to the development of lipid nanoparticulate nucleic acid delivery systems for therapeutic and other applications. Y.T. is named on patents describing uses of modified mRNA LNPs. D.W. is a coinventor on patents that describe the use of nucleoside-modified mRNA as a platform to deliver therapeutic proteins or vaccines. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8712"}}